Scholar Rock (NASDAQ:SRRK) Director Jeffrey Flier Sells 3,053 Shares

Scholar Rock Holding Corporation (NASDAQ:SRRK) Director Jeffrey Flier sold 3,053 shares of the company’s stock in a transaction on Wednesday, July 1st. The shares were sold at an average price of $53.88, for a total value of $164,495.64. Following the completion of the transaction, the director owned 27,856 shares of the company’s stock, valued at $1,500,881.28. The trade was a 9.88% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Scholar Rock Stock Performance

SRRK stock traded up $0.48 during midday trading on Monday, hitting $55.36. The stock had a trading volume of 1,182,357 shares, compared to its average volume of 1,407,918. Scholar Rock Holding Corporation has a 52 week low of $27.07 and a 52 week high of $56.54. The company has a current ratio of 8.64, a quick ratio of 8.64 and a debt-to-equity ratio of 0.71. The stock has a 50-day simple moving average of $48.43 and a 200 day simple moving average of $46.59. The firm has a market capitalization of $6.63 billion, a price-to-earnings ratio of -15.42 and a beta of 0.67.

Scholar Rock (NASDAQ:SRRK) last announced its quarterly earnings results on Thursday, May 7th. The company reported ($0.83) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.82) by ($0.01). During the same quarter in the previous year, the company earned ($0.67) EPS. As a group, equities research analysts anticipate that Scholar Rock Holding Corporation will post -3.23 earnings per share for the current year.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently modified their holdings of SRRK. IFP Advisors Inc grew its position in Scholar Rock by 294.1% during the 4th quarter. IFP Advisors Inc now owns 603 shares of the company’s stock worth $27,000 after acquiring an additional 450 shares during the last quarter. Caitong International Asset Management Co. Ltd acquired a new position in Scholar Rock in the fourth quarter worth $30,000. Summit Securities Group LLC bought a new stake in shares of Scholar Rock during the fourth quarter worth $31,000. Ramirez Asset Management Inc. bought a new stake in shares of Scholar Rock during the third quarter worth $37,000. Finally, EverSource Wealth Advisors LLC increased its stake in shares of Scholar Rock by 151.3% in the fourth quarter. EverSource Wealth Advisors LLC now owns 872 shares of the company’s stock valued at $38,000 after buying an additional 525 shares in the last quarter. 91.08% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

A number of research analysts have commented on the stock. Weiss Ratings restated a “sell (d-)” rating on shares of Scholar Rock in a research note on Tuesday, April 21st. Barclays raised their target price on Scholar Rock from $53.00 to $55.00 and gave the stock an “overweight” rating in a research report on Friday, May 8th. Wedbush boosted their price target on Scholar Rock from $56.00 to $58.00 and gave the company an “outperform” rating in a research note on Wednesday, April 1st. Canaccord Genuity Group started coverage on Scholar Rock in a research report on Monday, April 20th. They issued a “buy” rating and a $62.00 price target on the stock. Finally, HC Wainwright lifted their price objective on Scholar Rock from $58.00 to $65.00 and gave the company a “buy” rating in a report on Friday, May 8th. Four investment analysts have rated the stock with a Strong Buy rating, twelve have assigned a Buy rating and one has given a Sell rating to the company. According to MarketBeat.com, the stock has a consensus rating of “Buy” and a consensus price target of $56.00.

Scholar Rock Company Profile

Scholar Rock is a clinical-stage biotechnology company focused on the discovery and development of protein therapeutics that selectively target growth factors involved in disease processes. The company’s research platform is designed to modulate endogenous growth factor activation and signaling with high specificity, aiming to restore normal biological function across a range of disorders. Scholar Rock’s approach is distinguished by its emphasis on engineering antibodies and biologics that interact with growth factor precursors or latent complexes rather than the active form, potentially offering improved safety and efficacy profiles.

The company’s lead program, SRK-015 (appercept), is an investigational monoclonal antibody targeting the activation of latent myostatin proproteins and is being evaluated for the treatment of spinal muscular atrophy (SMA).